David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses guidelines for eosinophilic esophagitis, as well as some disease patterns that may occur.
Guidelines for eosinophilic esophagitis (EoE), which may follow a waxing and waning pattern, were released in 2020, said David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine.
Transcript
Can you discuss the guidelines for EoE, which were presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, and would you describe EoE as a chronic disease?
These guidelines were first published in the spring of 2020, so they've been available for about 18 months now. And these are new guidelines. They actually use something called a grade analysis to ask very specific clinical questions and then they evaluate the body of evidence related to that question, offering both clinical recommendations as well as information about the strength of the evidence. So they're very practical and hopefully useful for people to use. We also know that it can take years before clinical guidelines actually change practice, because people have, you know, limited ability to stay up with the latest and greatest. So that's why this session ['Implementing New Guidelines Into Practice"] is really important, to really help all of our colleagues in allergy and immunology best understand what the guidelines do and don't say, as well as how they can apply that to direct patient care.
EoE often is chronic for both children and adults, but it tends to follow a waxing-waning pattern. So part of what the guidelines address are really long-term management and monitoring. Some people do suffer more of an acute course, and then they improve, whereas others have a long-standing disease.
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces as AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More